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ARTICLES
THE TRIGGER OF COVERAGE FOR CANCER:
WHEN DOES GENETIC MUTATION BECOME
"BODILY INJURY, SICKNESS, OR DISEASE"?
Donald T. Ramsey*
I. INTRODUCTION
Cancer is a disease defined by the presence of cells that
have acquired the ability to replicate endlessly and form
tumors that invade surrounding tissue.' As a result of
startling scientific advances over the last ten years,2 cancer is
now known to develop according to a multi-stage process3 that
* J.D., University of California, Berkeley; M.A., University of California,
Berkeley; B.A., University of Southern California. The author is a partner at
Holland & Knight LLP where he specializes in appellate practice, insurance
coverage, and complex litigation.
1. See BERT VOGELSTEIN & KENNETH W. KINZLER, THE GENETIC BASIS OF
HUMAN CANCER xvii (1998).
2. Vogelstein and Kinzler point out:
As late as the 1970's human cancers remained a black box. Theories
were abundant: Cancer was hypothesized to result from defective
immunity, viruses, dysregulated differentiations, mutations.... [Ilt
was difficult to be optimistic that cancer would soon be understood....
This has changed dramatically as a result of the revolution in cancer
research that has occurred in the last decade. If this revolution were to
be summarized in a single sentence, that sentence would be 'Cancer is,
in essence, a genetic disease.'
Id. at xv (emphasis added).
3. The classic description of multistage development includes the phases of
initiation, promotion, and progression. In this paradigm, initiation occurred
with a genetic mutation that was, in itself, insufficient to cause cancer. To
cause cancer these initiated cells had to be exposed to promoters which
appeared to stimulate growth in the initiated cells but did not seem to be
mutagenic themselves. Cancer still would not develop, however, until the cells
reached the stage of progression, at which point they exhibited rapid growth,
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begins with the mutation of a gene in a single cell.' In this
process, four to seven key genes within a cell must mutate
before a malignant tumor appears.5 Such mutations can
result from infinitesimally tiny alterations in molecules of
DNA at a subcellular level. Since the mutation of one of the
cell's important genes is a rare event, there may be long
intervals between mutations, and it typically takes many
decades before a malignant tumor appears.6 Despite the
rarity of any particular mutation, cancer is a common
condition of modern man. Virtually everyone would get
cancer if they lived long enough.'
Plaintiffs in toxic tort suits and product liability actions
frequently allege that their cancer was caused by exposure to
a chemical or toxin. Resultant requests for insurance
coverage by product manufacturers and other industrial
defendants will require insurers to decide at what point
"cancer" becomes "bodily injury, sickness, or disease," and
thus, a covered "occurrence" under general liability policies.
Though insureds undoubtedly will contend that a continuous
trigger should govern these coverage determinations, certain
general features common to most types of cancer, and the
desire of courts to find a "factual" basis for the continuous
trigger, make this proposition problematic.
The continuous trigger, and what some consider to be its
functional equivalent, the "injury-in-fact" trigger of coverage,
are the predominant methods for determining insurance
coverage for progressive or continuous injuries or diseases
under general liability policies.8 Though they have been
increased invasiveness, and metastases. See J. MICHAEL BISHOP & ROBERT A.
WEINBERG, MOLECULAR ONCOLOGY 43-45 (1996); HENRY C. PITOT,
FUNDAMENTALS OF ONCOLOGY 140, 163 (1986).
4. See MALCOLM ALISON & CATHERINE SARRAF, UNDERSTANDING CANCER
37 (1997).
5. See ROBERT A. WEINBERG, ONE RENEGADE CELL: How CANCER
BEGINS 47 (1998).
6. See id. at 143.
7. See id. at 156.
8. See Mitchell Lathrop, Tobacco-Related Litigation: How It May Impact
the World's Insurance Industry, 3 CONN. INS. L.J., 305, 359 (1997) ("While there
are a number of competing 'trigger of coverage' theories, the so-called
'continuous trigger' or 'triple trigger' appears to be today's majority view in the
case of latent or progressive bodily injury."); Montrose Chem. Corp. of Cal. v.
Admiral Ins. Co., 10 Cal. 4th 645, 673, 687 n.22 (1995) ("[T]he weight of
authority.., is that bodily injury and property damage that is continuous or
progressively deteriorating throughout successive CGL policy periods, is
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guided by a variety of rationales,9 most courts that have
adopted a continuous trigger have made its use dependent, in
whole or in part, on whether "in fact" the "bodily injury,
sickness, or disease" to the third-party claimant was
continuous through successive policy periods. ° In making
"injury" a question of fact, courts have intentionally
disregarded or inadvertently ignored definitional questions
about what constitutes "injury."" In simple cases this is not a
problem. Once the "injury" lies outside the realm of the self
evident, however, as it does in the context of latent disease
processes like those at work in the development of cancer,
potentially covered by all policies in effect during those periods."); see also
Michael G. Doherty, Comment, Allocating Progressive Injury Liability Among
Successive Insurance Policies, 64 U. CHI. L. REV. 257, 261 (1997).
9. These include administrative convenience. See Northern States Power
Co. v. Fidelity & Cas. Co., 523 N.W.2d 657, 662-63 (Minn. 1994) (maximizing
coverage, ambiguity in policy language); Keene Corp. v. Ins. Co. of N. Am., 667
F.2d 1034, 1041 (D.C. Cir. 1981) (the "plain meaning" of the policy, and the
drafting history); Montrose, 10 Cal. 4th at 673, 688. See generally James M.
Fischer, Insurance Coverage for Mass Exposure Tort Claims: The Debate Over
the Appropriate Trigger Rule, 45 DRAKE L. REV. 625, 649-50 (1997).
10. Under traditional tests, the time of an occurrence is when the bodily
injury or property damage happens, not when the wrongful act took place. See
Remmer v. Glens Falls Indem. Co., 140 Cal. App. 2d 84, 88 (1956); BARRY L.
OSTRAGER & THOMAS R. NEWMAN, HANDBOOK ON INSURANCE COVERAGE
DISPUTES § 9.03(a) (10th ed. 2000). "Recently, many courts that have adopted a
continuous trigger theory have done so in combination with an injury-in-fact
definition of bodily injury that has defined bodily injury so broadly as to
effectively duplicate the multiple trigger tort." Fischer, supra note 9, at 647.
11. At least one court has rejected the injury-in-fact trigger in favor of a
simpler and easier to administer "exposure" trigger even though it
acknowledged "the attraction of the intellectual honesty of the injury-in-fact
approach, which is arguably the truest to the CGL policy language of 'bodily
injury' (not relying, as a proxy for 'real injury' on either diagnosis or subclinical
tissue damage), which.., might not develop into full blown disease." Guaranty
Nat'l Fire Ins. Co. v. Azrock Indus., Inc., 205 F.3d 253, 264 (5th Cir. 2000).
Another court, in a case involving exposure to welding fumes and asbestos, has
attempted to deal with this kind of factual complexity by developing a "flexible
continuing injury trigger," a hybrid of the continuing injury and injury-in-fact
triggers.
A 'continuing injury' trigger applies those policies in effect at any time
from exposure through manifestation, while an 'injury-in-fact' trigger
applies those policies which were in effect at any time when actual
injury occurred. In effect, we find that the proper trigger is a hybrid
between these two triggers. The hybrid is a 'flexible continuing injury'
trigger that presumes uniformity of injury probability while allowing
'injury-in-fact' evidence to rebut the presumption and constrict the
range of the allocation field.
Lincoln Elec. Co. v. St. Paul Fire & Marine Ins. Co., 210 F.3d 672, 690 n.24 (6th
Cir. 2000).
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courts are without a standard by which to judge whether a
particular insult to the body, or a series of subcellular
changes, is "injurious" during any particular policy period. In
part the problem is legal; in part it is scientific. The New
Jersey Supreme Court summed it up well in Owens-Illinois,
Inc. v. United Insurance Co.:1
Our concepts of legal causation were developed in an age
of Newtonian physics, not of molecular biology. Were it
possible to know when a toxic substance clicks on a switch
that alters irrevocably the composition of the body and
before which no change has "occurred" we might be more
confident that occurrence-causing damages had taken
place during a particular policy period. The limitations of
science in that respect only compound the limitations of
law. 13
The remarks of the Owens-Illinois court are significant,
not just because they are insightful, but because they reflect a
traditional "all or nothing" view, prevalent in the context of
asbestos coverage litigation, that looks for "irrevocable"
changes as the hallmark of undefined "injury." Through the
1980s and 1990s, asbestos-related injury cases served as the
model by which courts judged other continuing injury cases
and the triggers applicable to them. 4 In such cases, the
continuing injurious presence of asbestos fibers in the lung
tended to blur or moot questions about whether the courts
applied the continuous trigger because the exposure to
asbestos was continuous, because the injury grew
progressively and measurably worse over time, or because the
original injury simply persisted for a period of years. The
ineradicable nature of asbestos fibers and their "irrevocably"
injurious presence (i.e., the "exposure-in-residence," as the
court in Keene Corp. v. Insurance Co. of North America"
described it) meant that injury of some kind was ongoing
from the moment the first fiber was inhaled until the
claimant died. Thus, successive policies were triggered
12. 650 A.2d 974 (N.J. 1994).
13. Id. at 985.
14. Courts also applied the continuous trigger to bodily injury in a variety of
other contexts, including DES. See Eli Lilly & Co. v. Home Ins. Co., 482 N.E.2d
467 (Ind. 1985) (breast implants); Dow Coming Corp. v. Hartford Accident &
Indem. Co., No. 93-325-788-CK (Mich. Cir. Ct. Nov. 16, 1994) (lead paint);
Chantel Assocs. v. Mount Vernon Fire Ins. Co., 656 A.2d 779 (Md. App. 1995).
15. 667 F.2d 1034 (D.C. Cir. 1981), cert. denied, 455 U.S. 1007 (1982).
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regardless of whether the particular disease at issue was
pleural plaques, asbestosis, bronchogenic carcinoma, or
mesothelioma. 16
But not all latent or insidious diseases are characterized
by the continuing presence of the toxic agent in the body. For
such diseases, a continuous trigger may be factually
insupportable even though these illnesses are marked, like
asbestos-related diseases, by a long latency period that
separates first exposure from the appearance of clinical
symptoms. Some cancers fall within this group.
A malignant tumor results when a cell accumulates a
series of mutations to key genes that control the cell's growth
and repair functions. A cell is prone to accumulate such
mutations over time because the genes within a cell not only
sustain new mutations from time to time, but the mutations
that are sustained pass down from one generation of cells to
the next in the process of cell division and replication.17
Accordingly, the cells in a malignant tumor will carry exact
copies of the original key mutation that first appeared
decades earlier. 8 Thus, the development of cancer is, in this
sense, continuous. The difficulty is that the terms "injury,"
"sickness," and "disease" cannot appropriately be used to
describe all phases of this process. Consequently, use of the
term "continuous" tends to mislead because it is not
appropriate to say that an "injury" or "disease" is occurring
through the entire thirty to fifty year interval between the
initial key genetic mutation and the ultimate development of
a malignant mass of cells.
Thirty-three to forty percent of all people will develop
cancer at some point in their lives.' 9 Most people who do get
cancer do not become ill until they are in their sixties or
seventies. " Because it typically takes three to five decades or
16. In applying a continuous trigger to asbestos-related bodily injury in the
Coordinated Asbestos Coverage Cases, the trial court stated: "The foregoing
conclusions apply regardless of which asbestos-related disease affects the
claimant and regardless of which type of asbestos fiber was inhaled by the
claimant." In re Asbestos Ins. Coverage Cases, Judicial Council Coordination
Proceeding No. 1072, Statement of Decision Concerning Phase III Issues, slip
op. at 43 (Cal. App. Dep't Super. Ct. Jan. 24, 1990).
17. See BISHOP & WEINBERG, supra note 3, at 35-37.
18. See id.
19. See WEINBERG, supra note 5, at 141; DENNIS W. ROSS, INTRODUCTION
TO ONCOGENES AND MOLECULAR CANCER MEDICINE 58 (1998).
20. See ALISON & SARRAF, supra note 4, at 37-41.
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more from the time of the first mutation for a cell to
accumulate the requisite number of mutations for cancer to
arise, labeling all phases in the development of cancer as
"injury" or "disease" means that almost half of the population
is deemed to be injured or diseased throughout most of their
lives. The use of the term "injury" or "disease" is
inappropriate because even people who die from some other
cause, before they can develop cancer, carry many thousands
of cells bearing mutations to key genes throughout most of
their existence.21 Thus, if genetic mutation amounts to injury
and disease, then injury is universal and disease is a normal
aspect of being alive.
Consideration of these factors alone should preclude any
automatic application of a continuous trigger to all phases of
cancer development. But there are additional problems as
well. Unlike the presence of asbestos fibers in the lung,
genetic damage induced by mutagens, is not, strictly
speaking, "irrevocable." Genetic damage, if minor, may be
repaired. If such damage is too extreme, it may trigger the
death of the cell." Unlike mutations caused by asbestos
fibers which lodge in the lung because they are inhaled from
outside the body, other genetic mutations can and do occur
spontaneously as part of the body's normal process. 4 Thus,
for multiple reasons, and depending upon the particular type
of cancer, the terms "injury" and "disease" fail properly to
describe all phases in the complex etiology of cancer, which,
especially in its long "early" phase of development is "a
dynamic process that may stop temporarily, or permanently,
revert to normality, or progress to frank neoplasia."5 Indeed,
the development of cancer is at once both too rare and too
common, too normal and too exceptional, for all stages of the
entire process comfortably to bear the designation "bodily
injury, sickness, or disease."
Because of this complexity, courts must resist the
temptation to lump all cancers together, or to model all
applications of the continuous trigger on the example of
21. See Henry C. Pitot, Multistage Carcinogenesis, in ENCYCLOPEDIA OF
CANCER, vol. II, at 1613 (1997).
22. See WEINBERG, supra note 5 at 90.
23. See id. at 126.
24. See ROSS, supra note 19, at 22.
25. C. SONNENSCHEIN & A.M. SoTo, THE SOCIETY OF CELLS 101 (1998).
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asbestos-related injury. Although courts have sought to avoid
defining "injury" and to be guided simply by the "facts,"
courts should acknowledge that this effort is untenable when
the issues involve a series of astonishingly complex events
that unfold through the interactions of vanishingly
infinitesimal subcellular molecules over the course of an
entire lifetime.
This article does not attempt to posit any comprehensive,
"proper" definition of "injury, sickness, or disease.""6 With
more modest goals in mind, it attempts to emphasize three
significant ideas:
(1) The determination as to whether injury is
"continuous," and thus whether multiple policies are
triggered, may turn on whether the carcinogen is absorbed
by, and remains actively present in the body after
exposure to it in the outside atmosphere ceases;
(2) The enduring character of the developmental
processes at work must be balanced against, and may be
outweighed by the reality that over long periods of time
the process is also marked by significant discontinuity, the
lack of any "new" injury and the great likelihood that the
disease will never develop;
(3) The exponential increase in knowledge about the
molecular, genetic basis of cancer may soon yield
screening techniques that permit scientists and physicians
to pinpoint when a tumor becomes malignant, or at least
26. Dictionary definitions of injury, sickness, and disease define these words
in terms of impairment, damage, destruction, and ill health.
Injury:la: an act that damages, harms or hurts: an unjust or
undeserved infliction of suffering or harm... 2: hurt, damage, or loss
sustained. Syn. Injury, hurt, damage, harm and mischief mean in
common the act or result of inflicting on a person or thing something
that causes loss, pain, distress or impairment or destruction of right,
health, freedom, soundness, or loss of something of value.
WEBSTER'S THIRD NEW INTERNATIONAL DICTIONARY OF THE ENGLISH
LANGUAGE UNABRIDGED 648 (Merriam-Webster 1896). "Sickness: la: the
condition of being ill: ill health: illness. b: a disordered, weakened or unsound
condition .... " Id. at 1164.
Disease: la: obs. lack of ease ... b(1): an impairment of the normal
state of the living animal or plant body or of any of its components that
interrupts or modifies the performance of the vital functions, being a
response to environmental factors (as malnutrition, industrial hazards,
or climate), to specific infective agents (as worms, bacteria or viruses),
to inherent defects of the organism (as various genetic anomalies), or to
combinations of these factors: sickness, illness.
Id. at 2111.
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to better estimate when cancer becomes a genuine
probability instead of an unpredictable chance.
Courts that seek a factual basis for the use of a
continuous or injury-in-fact trigger must thus look carefully
at the particular etiology of the cancer at issue before they
apply a coverage trigger. In addition, courts faced with
coverage questions in cancer cases should look for and take
advantage of new advances in cancer screening techniques
where they are available. And where such tools are
unavailable, courts should abide by what is known before
adopting presumptions of disease or fictions of injury as a
means of supplying a "factual" basis for the continuous
trigger.
II. CASES JUSTIFY A CONTINUOUS TRIGGER BY THE PRESENCE
OF CONTINUING INJURY THROUGH SUCCESSIVE POLICY
PERIODS
Guided by its belief that the "heart" of an insurance
transaction is "the insured's purchase of certainty," the court
in Keene Corp. v. Insurance Co. of North America,7 was the
first court to impose a continuous trigger. 8 The court was
remarkably candid about its lack of concern for the factual
basis of "injury" in successive policy periods. According to the
Keene court, "the details of the development of these
[asbestos-related] diseases [were] not relevant to the issues
decided." 9 Indeed, according to the court in Keene, "if a
disease could be predicted to develop many years after
inhalation of asbestos, yet no cellular changes were known to
occur during that period, we would still hold that all policies
are triggered from the point of exposure to the point of
manifestation.""
As if embarrassed by the Keene court's result-oriented
approach to coverage and its disregard for the actual facts of
injury, courts that have adopted a continuous trigger after
Keene have made much greater efforts to justify the
continuous trigger by the existence of actual continuing
injury throughout successive policy periods. "Nothing in the
policy language purports to exclude damage or injury of a
27. 667 F.2d 1034 (D.C. Cir. 1981), cert. denied, 455 U.S. 1007 (1982).
28. See id.
29. Id. at 1038 n.3.
30. Id. at 1044 n.19.
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continuous or progressively deteriorating nature," said the
court in Montrose Chemical Corp. of California v. Admiral
Insurance Co., "as long as it occurs during the policy
period." 2 Under this standard, the court further explained
"whether the damages and injuries alleged are, in fact,
'continuous' is itself a matter for final determination by the
trier-of-fact."
33
Courts adopting an injury-in-fact trigger of coverage
likewise focus on the issue of whether, "in fact," an injury
occurred in each successive policy period. In American Home
Products Corp. v. Liberty Mutual Insurance Co.," the Second
Circuit affirmed the district court's determination that
coverage under the policy required "'a showing of actual
injury, sickness or disease occurring during the policy period,
based upon the facts proved in each particular case.""
Though the court of appeals rejected the district court's
conclusion that an injury had to be "diagnosable" or
"compensable" to qualify as an injury, it affirmed that "the
trigger of coverage clause unambiguously provides for
coverage based upon the occurrence during the policy period
of an injury-in-fact."36
But what is the nature of the "injury" that must, in fact,
"be present" during the policy period in order to trigger
coverage? Case law rarely states what the nature of the
injury is, and when it does, the definitions are often simplistic
or circular. 7 The Keene court, which had already dispensed
31. 10 Cal. 4th 645, 673 (1995).
32. Id.
33. Id. at 694.
34. 748 F.2d 760 (2d Cir. 1984).
35. Id. at 763 (quoting American Home Prods. Corp. v. Liberty Mut. Ins.
Co., 565 F. Supp. 1485, 1489 (S.D.N.Y. 1983)).
36. Id.
37. Other commentators have noted this same problem and criticized the
tendency of courts to assume that they can avoid the definitional question by
making "injury" a "question of fact":
Courts that adopt the injury in fact theory do not at all answer the
question of what constitutes a bodily injury.... [E]ven if the medical
evidence that shows that microscopic injuries occur upon inhalation of
asbestos or upon first exposure to some drug is accepted as
unproblematic, this medical "injury" evidence itself does not and cannot
constitute a definition of bodily injury in the CGL policy. There is no
principle-metaphysical, linguistic, hermeneutical, or other-by which
physical facts alone determine meanings.
James E. Scheuermann, The Injury in Fact Theory as a Solution to the Trigger
of Coverage Issue, 24 TORT & INS. L.J. 763, 775-76 (1989).
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with the need to see "facts," was equally hostile to common
definitions of "injury." The Keene court not only rejected the
definitions of injury developed in workers' compensation
cases, statute of limitations cases, and health insurance
cases, but also held that neither the definition of injury
followed by physicians, nor that subscribed to by laypersons,
was controlling. 8
The court in E.R. Squibb & Sons, Inc. v. Accident &
Casualty Insurance Co.," viewing the question of injury in the
context of DES ' cases, also did not see any difficulty: "[Tihe
term 'injury' is plain on its face-it involves any form of harm
which befalls a person adversely affected by the product
involved.... Hence, no extrinsic evidence concerning the
meaning of the term need be considered."'
In response to the insurers' arguments that the trial
court had mistaken mere subclinical cellular changes for
actual "injury" caused by asbestos, the California appellate
court in Armstrong World Industries v. Aetna Casualty &
Surety Co."' offered two solutions. First, though the court
framed the "key question" as "the point in time at which
injury takes place,"" the court thereafter explained that as
long as an injury eventually did become evident in
subsequent years, it was unnecessary to pinpoint exactly
when it occurred. "For purposes of determining insurance
coverage, absolute precision is not required as to when the
injury occurred."'  Second, in response to the insurers'
argument that some form of impairment, and not mere
cellular change, was necessary for "injury" to occur, the court
held it sufficient that at a microscopic level the physiological
processes associated with the inhalation of asbestos "impair
the gas exchange function of the lung cells" almost
38. See Keene Corp. v. Insurance Co. of N. Am., 667 F.2d 1034, 1043-44
(D.C. Cir. 1981), cert. denied, 455 U.S. 1007 (1982).
39. 853 F. Supp. 98 (S.D.N.Y. 1994).
40. DES, or diethylstilbestrol, was a synthetic estrogen prescribed to
pregnant women in the 1950s and 1960s to prevent miscarriages. Years later
the drug was discovered to cause reproductive system abnormalities and cancer
to offspring who were exposed to DES in utero. See Sindell v. Abott Labs., 26
Cal. 3d 588, 594 (1980).
41. E.R. Squibb & Sons, 853 F. Supp. at 100.
42. 52 Cal. Rptr. 2d 690 (Cal. Ct. App. 1996).
43. Id. at 700.
44. Id. at 704.
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immediately upon the inhalation of asbestos fibers.45
The difficulty in defining injury and determining when
and for how long it occurs was troublesome enough when
dealing with subclinical changes in tissue at the cellular level.
The problem became more intense as courts attempted to
apply fact-based standards of "injury," without any governing
definition, to asbestos-related cancers, such as bronchogenic
carcinoma or mesothelioma. In these types of cases, courts
attempted to locate injury in the form of genetic change
existent at the sub-cellular level decades before a tumor
appears.
In Stonewall Insurance Co. v. Asbestos Claims
Management Corp.," for example, the Second Circuit
preliminarily acknowledged that "in view of the different
etiologies of asbestosis and cancer, it is possible to hold, as
the district court did, that these two diseases trigger policies
differently." 7 Then, focusing on the trigger for asbestos-
related cancer, the appellate court found that the evidence
was sufficient to support both the jury's finding of "injury-in-
fact" during the long latency period leading up to tumor
development, and the opposite conclusion of the district court,
which had reversed the jury's conclusion and determined that
injury did not, in fact, exist until a tumor appeared." Fearing
that the district court may have misapplied the injury-in-fact
test, the Second Circuit remanded the question of continuous
injury in asbestos cancer cases to the district court for further
consideration.
On remand, the district court directly commented on the
difficulty of the definitional-fact finding task and the peculiar
notion of "injury" that was needed to fit the lengthy, complex
process leading up to cancer within the confines of a
continuous injury trigger:
As noted at the outset, the case requires us to force
complex medical concepts into the words of insurance
policies drafted by people who never contemplated this
type of litigation. When most of us think of an injury, we
consider some discrete insult to the body that causes
immediate and observable injury-a broken leg, a stick in
45. See id.
46. 73 F.3d 1178 (2d Cir. 1995), reh'g denied, 85 F.3d 49 (2d Cir. 1996).
47. Id. at 1197.
48. See id.
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the eye. When someone is diagnosed with cancer, we do
not normally think of them having been injured
repeatedly over the years in which the cancer was
developing.49
The conclusion that "injury" is a poor term to describe
cancer development may create problems for many courts
whose rules of policy interpretation require them to ascertain
the "plain meaning" of policy language according to "the
meaning a layperson would ordinarily attach to it.""°
According to this "plain meaning" test, if the term "injury"
would not ordinarily be used to describe a subcellular event
that happened forty years before cancer appeared, then that
form of "injury" should not trigger insurance coverage for that
time frame. But even though the district court in Stonewall
acknowledged this problem, it concluded on remand that the
continuing presence of asbestos fibers in the lung constituted
a persistent and ongoing insult to surrounding tissue and
directly caused or promoted mutations that eventually
contributed to cancer. On this basis, the district court held in
favor of the continuous trigger despite its acknowledgment
that it could not tell "at what point in any particular case
asbestos became involved in the process of cancer
development." 1  As the unpublished trial court opinion
stated:
The medical testimony shows that asbestos can contribute
to the cancer process in any of the following ways: 1) the
process by which the body's immune system attacks
49. Stonewall Ins. Co. v. Asbestos Claims Management Corp., No. 86 Civ.
9671(JSM), 1998 WL 405047, at *1 (S.D.N.Y. July 17, 1998).
50. Waller v. Truck Ins. Exch., Inc., 11 Cal. 4th 1, 18 (1995). Indeed, a
partial list of such states includes: Rhode Island (Baccari v. Donat, 741 A.2d 262
(R.I. 1999)); Wisconsin (Moore v. Economy Fire & Cas. Co., 601 N.W.2d 853
(Wis. 1999)); Alaska (Fejes v. Alaska Ins. Co., 984 P.2d 519 (Alaska 1999)),
Idaho (Mutual of Enumclaw Ins. Co. v. Pedersen, 983 P.2d 208 (Idaho 1999)),
Missouri (Martin v. United States Fidelity & Guar. Co., 996 S.W.2d 506 (Mo.
1999)), Tennessee (Barnes v. Employers Mut. Cas. Co., No. 03A01-9812-CH-
00403, 1999 WL 366587 (Tenn. Ct. App. June 8, 1999)), Connecticut (O'Brien v.
United States Fidelity & Guar. Co., 669 A.2d 1221 (Conn. 1996)), Florida (St.
Paul Fire & Marine Ins. Co. v. Tingley Sys., Inc., 722 So. 2d 849 (Fla. Dist. Ct.
App. 1998)), Washington (State Farm Mut. Auto. Ins. Co. v. Ruiz, 952 P.2d 157
(Wash. 1998)), Kansas (Hammon v. Safeco Ins. Co., 954 P.2d 7 (Kan. Ct. App.
1998)), North Dakota (Martin v. Allianz Life Ins. Co., 573 N.W.2d 823 (N.D.
1998)), Maryland (Kendall v. Nationwide Ins. Co., 702 A.2d 767 (Md. 1997)),
Utah (Mesa Dev. Co. v. Sandy City Corp., 948 P.2d 366 (Utah Ct. App. 1997).
51. Stonewall Ins. Co., 1998 WL 405047, at *2.
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asbestos at the time it invades a cell generates oxygen-free
radicals which may (a) damage a cell's DNA, making the
cell susceptible to mutation from asbestos or other
environmental agents, e.g., tobacco smoke; (b) increase the
rate of cell proliferation which increases the likelihood of
spontaneous genetic mutation in otherwise healthy cells;
(c) increase the rate of proliferation in already mutated
cells causing the body to have an increased number of
such cells, thereby increasing the risk of further mutation;
2) the asbestos fiber may itself lodge in a cell in a manner
that a) causes a mutation; b) makes the cell susceptible to
mutation; c) accelerates the rate of cell expansion, or d)
reduces a cell's ability to prevent excessive expansion; and
(3) the scarring process resulting from the body's removal
of asbestos may itself contribute to the development of
52
cancer.
Not all cancers, however, are like asbestos-related
cancers. In fact, though courts have often followed the
asbestos injury model in coverage litigation, they have
repeatedly emphasized, in connection with virtually every
other aspect of asbestos mass tort and insurance litigation,
that the problems posed by asbestos are unique." Indeed,
asbestos-related cancers may be almost singularly unique in
the degree to which they are initiated and promoted by the
continuing presence of the asbestos fibers in the lung. For
many other types of cancer, however, the offending agent
responsible for the initial mutation of an important gene does
not remain present in the body. Although cancer may
develop, partially as a result of an initial genetic insult, the
question of whether "bodily injury, sickness, or disease" can
fairly be said to have been present from the moment of first
key mutation to the development of a malignant tumor is
much more problematic. In such circumstances, courts that
look for "injury" in each policy period must confront the
complexity of the actual facts and accord proper significance
52. Id.
53. "Courts generally view asbestos cases as unique in the law." Wasau
Tile, Inc. v. County Concrete Corp., 593 N.W.2d 445, 457 (Wis. 1999). "[The
rule we develop in this case for subsequent damages is premised on the unique
nature of the asbestos situation and is not applicable in other areas." Carson v.
Johns-Manville Sales Corp., 399 N.W.2d 1, 9 (Mich. 1986). "As other courts
around the country have noted, asbestos cases are unique in the law." San
Francisco Unified Sch. Dist. v. W.R. Grace & Co., 44 Cal. Rptr. 2d 305, 308 (Cal.
Ct. App. 1995).
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to the important discontinuities that are present in the
development of cancer.
More importantly, courts must question the extent to
which the ongoing metabolic processes of life itself may be
described as "injury" in any normal or ordinary use of that
word. In a DES coverage case, E.R. Squibb & Sons, Inc. v.
Accident and Casualty Insurance Co.," the court does suggest
that even the normal processes of life may be considered
injury: "Where an event has continuing effects which continue
to enhance the ill effects felt by the victim of the injury as a
result of the amplification though otherwise normal bodily
process or otherwise, the injury will be continuing so long as
such effects continue."5 Though this approach may be
understandable, given the inability to map out the etiology of
certain injuries in DES cases," it is a dangerous principle to
54. 860 F. Supp. 124 (S.D.N.Y. 1994).
55. Id. at 126.
56. The problem of selecting the appropriate trigger may be especially
difficult with respect to DES-related medical problems. DES (diethylstilbestrol)
was a synthetic estrogen given to between two and four million women in the
United States between 1938 and 1971. In 1971, it was discovered that it caused
clear cell adenocarcinoma of the vagina in young women who were exposed in
utero when their mothers took the drug. See R. Scully et al., Vaginal and
Cervical Abnormalities Including Clear-Cell Adenocarcinoma, Related to
Prenatal Exposure to Stilbertral, 4 ANNALS OF CLINICAL & LABORATORY SCI.
222 (1974). Since 1971, DES has been shown to be responsible for a broad array
of medical problems in the mothers who took the drug and their daughters and
sons, including adenosis (a pre-cancerous epithelial infirmity, cervical ridges or
hoods, and other abnormal formations of the tissues of the cervix) as well as
problems in the male reproductive organs. See Harper v. Eli Lilly & Co., 575 F.
Supp. 1359 (N.D. Ohio 1983). The exact mechanism of the development of clear-
cell adenocarcinoma, however, is not well understood at this time. See RYAN ET
AL., KISTNER'S GYNECOLOGY AND WOMEN'S HEALTH 87 (Mosby ed., 7th ed.
1999); M. Marselos & L. Tomatis, Diethylstilbestrol: I, Pharmacology, Toxicology
and Carcinogenicity in Humans, 28A EUR. J. CANCER 1182, 1182-89 (1992).
Given this array of diseases and the unknown etiology of clear-cell cancer, it is
not surprising that various courts have held DES-related diseases to be like
asbestos-related diseases as well as unlike them. "AHP cannot rely on the
rationale of cases that have found immediate injury from the ingestion of
asbestos fibers, because the drugs at issue in this case differ markedly from
asbestos in the manner in which they are alleged to injure humans." American
Home Prods. Corp. v. Liberty Mut. Ins. Co., 565 F. Supp. 1485, 1493-94
(S.D.N.Y. 1983), affd in part, 748 F.2d 760 (2d Cir. 1984). "Since an asbestos-
related disease is similarly separated in time from its initial assault to the time
of the manifestation of its debilitating effect, we see no reason not to adopt the
same approach to DES-related diseases." Vale Chem. Co. v. Hartford Accident
& Indem. Co., 490 A.2d 896, 902 (Pa. Super. Ct. 1985).
This may, in turn, account for the broad variety of coverage triggers that courts
have used in DES coverage cases. These include continuous trigger, see Vale
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apply across the board to other cancers and diseases.
Courts applying the continuous trigger also urge that
"the entire mosaic of events must be considered in order to
ensure the accuracy of the legal characterization given to the
situation."57 When the "entire mosaic" is cancer, many of the
facts that must be taken into account through the process of
the development of the actual malignant tumor are more
consistent with normal ongoing processes of molecular change
through the course of living and aging than they are with
accepted notions of injury, sickness, or disease.
III. PROBLEMS IDENTIFYING THE TIMING AND FACT OF
"INJURY" IN THE DEVELOPMENT OF CANCER
A. Cancer-An Overview
Cancer is the generic term for a disease that has more
than one hundred different forms." Every different type of
cell is vulnerable to its own forms of cancer.59 All cancers,
however, develop according to certain shared patterns and
processes. The process starts with a genetic mutation
originating in a single cell, which, over three to four decades
or more, accumulates three to six more key mutations,
leading to uncontrolled cell proliferation, tumor growth, and
the invasion of adjacent tissue.0 In its most virulent, lethal
form it leads to metastases, i.e., the migration of mutated
cells to other sites in the body where they establish other
colonies of mutated cells and ultimately other tumors.6
The genetic mutations that occur as a result of exposure
to a mutagen, or which occur spontaneously in the process of
cell division, are acquired somatic cell mutations rather than
inherited germ line mutations.62 Traditional genetics deal
Chem. Co., 490 A.2d 896; Eli Lilly & Co. v. The Home Ins. Co., 482 N.E.2d 467
(Ind. 1985) (exposure and manifestation trigger); Transamerica Ins. Co. v.
Belafonte Ins. Co., 490 F. Supp. 935 (E.D. Pa. 1980) (manifestation); American
Motorist Ins. Co. v. E.R. Squibb & Sons, Inc., 406 N.Y.S.2d 658 (N.Y. 1978)
(injury in fact); American Home Prods. Corp., 565 F. Supp. 1485.
57. E.R. Squibb & Sons, Inc. v. Accident and Cas. Ins. Co, 853 F. Supp. 98,
101 (S.D.N.Y. 1994).
58. See What You Need to Know About Cancer, SCI. AM. (Special Issue) Sept.
1996, at 3 [hereinafter SCI. AM.).
59. See VOGELSTEIN & KINZLER, supra note 1, at xvii.
60. See id.
61. See ALIsON & SARRAF, supra note 4, at 110.
62. See id. at 37.
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with traits that are passed along from one generation to the
next due to genes present in the germ line cells which
produce eggs and sperm. The genetics of cancer development,
however, deal with somatic cells like those present in the
epithelium,"8 lung, and colon. Thus, a genetic mutation that
occurs to a liver cell in the course of a person's life will not be
passed down to his or her descendants. In fact, relatively few
cancers arise from inherited germ line mutations.64
As noted earlier, cancer is primarily a disease of the
elderly. The chances of contracting cancer escalate rapidly
with age. "The log of the incidence rate and the log of age
have a linear relationship, with the incidence increasing
dramatically (103-107-fold) with age." 5 At present, between
thirty-three and forty percent of all people will contract
cancer and half of those who contract it will die from it. 66 As
people live longer, these percentages may increase. Indeed,
"given enough time cancer will strike every human body."'
There are currently eight million people in the United States
living with cancer and another approximately 1.2 million
were expected to contract it in 1999.9
The genes that sustain the mutations that ultimately
lead to cancer are infinitesimally small and unbelievably
complex. Each cell contains 70,000 to 100,000 genes which, if
stretched out in a linear strand, would be two meters long."0
If the cell nucleus, which is less than 1/1000th of an inch
wide71 was magnified to the size of a basketball, the genetic
63. Epithelial cells are those in the sheet-like layer of tissue which covers
and lines the internal and external surfaces of the body. They form the outer
layer of the skin and other surface tissue such as the mucous membranes, which
line such cavities as the mouth and the stomach. See id. at 238.
64. See ROSS, supra note 19, at 15; SHIRLEY W. HODGSON & EAMON R.
MAHER, HUMAN CANCER GENETICS 1 (2d ed. 1999). "Germ line" cell mutations
are those which "because of their presence in the germ line become hereditary,
which, as the first step in multistage carcinogens predispose the individual to
the development of cancer." ALISON & SARRAF, supra note 4, at 240. "Somatic"
cell mutations are mutations "in diploid cells that are not cells of the germ line
and thus do not undergo meiosis to form gametes thus the mutation is not
inherited." Id. at 258.
65. VOGELSTEIN, supra note 1, at xviii.
66. See WEINBERG, supra note 5, at 141; ROSS, supra note 19, at 58.
67. See ALISON & SARRAF, supra note 4, at 1.
68. WEINBERG, supra note 5, at 156.
69. See THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)
PROGRAM, NATIONAL CANCER INSTITUTE (1999).
70. See ROSS, supra note 19, at 5.
71. See MICHAEL WALDHOLZ, CURING CANCER 23 (1997).
308 [Vol. 41
2001] TRIGGER OF COVERAGE FOR CANCER 309
strand containing the substance of heredity would be as thick
as the thread of a spider's web and extend for 200
kilometers. 2
There are four basic categories of causes of the genetic
mutations that may eventually lead to cancer-viral 3 ,
hereditary, 4  environmental5  (including lifestyle), and
spontaneous". Estimates differ on the relative importance of
each factor-in part because it is difficult to isolate factors
and because each factor is of greater or lesser importance
depending on the type of cancer in question. Cigarette
smoking and a diet low in fruits and vegetables cause or
significantly contribute to somewhere between one-half to
two-thirds of all cancers.7 Hereditary genetic mutations (in
germline as opposed to somatic cells) cause five to ten percent
of cancers.78 Perhaps as many as fifteen percent of cancers
stem from viruses, bacteria, or parasites. 9 While it is very
difficult to calculate, air and water pollution are thought to
account for only about two percent of fatal cancers."
Significantly, a relatively high percentage of cancers
would occur simply because of the normal operation of the
body's own metabolic processes, independent of "external"
72. See ROSS, supra note 19, at 4. If all the DNA present in a human body
were stretched out it would reach from the earth to the sun and back again. See
Heredity, Molecular Genetics, DNA Replication <http://www.britannica.com/
bcom/eb/article/410,5716,120934+4+1 11157,00.html>.
73. Perhaps as many as 15% of cancers worldwide are traceable to viral
causes. See SCI. AM., supra note 58. Of the viral carcinogenic agents "the two
most important are the human papilloma viruses types 16 and 18, which are
sexually transmitted and the Hepatitis B virus." Id. at 33.
74. Inherited mutations in genes can confer a very high risk of cancer. A
predisposition to certain kinds of breast cancer, colon cancer, melanoma, kidney
cancer, and retino blastoma can be inherited. See id. at 22.
75. The two leading "environmental" causes of cancer are tobacco smoke and
poor diet consisting of high amounts of saturated fat. See id. at 28.
76. Some cancers occur simply because the body's own processes produce
carcinogens and generate genetic errors that go unrepaired. See id. at 26. As
Weinberg explains: "the cell's normal energy metabolism releases millions of
highly reactive molecular by-products every day. Many of these are oxidants
and 'free radicals,' the latter being unpaired highly reactive electrons. Like
environmental mutagens, these indigenous molecules can chemically alter a
variety of molecules including the cell's DNA." WEINBERG, supra note 5, at 88.
See also SCI. AM., supra note 58, at 25-36.
77. See SCI. AM., supra note 58, at 27.
78. See HODGSON & MAHER, supra note 64, at 22.
79. See SCI. AM., supra note 58, at 33.
80. See id. at 32.
SANTA CLARA LAW REVIEW
factors.81 Some experts estimate that perhaps a quarter of all
cancers are "hard core"-they would develop even in a world
free of all external carcinogens simply because of the
production of carcinogens within the body and the occurrence
of spontaneous unrepaired genetic damage that results in
mutations."
Most malignant tumors begin with a single key mutation
in a single ancestral cell. By the time a tumor becomes
clinically evident, it will consist of a billion or more cells.83
Each key genetic mutation is highly improbable-one chance
per million cell divisions to activate one oncogene" and one
chance in a billion cell divisions to inactivate both copies of a
tumor suppressor gene. 5 Although there are thousands of
cells containing one or multiple mutations at any given time,
it often takes four decades or more after the first key genetic
mutation occurs in a cell for the requisite number of
additional mutations to occur and a malignant tumor to arise.
This is the primary reason why cancer is a disease generally
associated with the aging process.8
Cancer results when a sufficient number of mutations
have "hit" the important genes that control a cell's replication
and repair functions so that the cell reproduces endlessly,
copying its mutated genetic blueprint over and over. The
tumor that ultimately develops is thus linked to the original
genetic mutation as well as to each of the series of mutations
that accumulate in the cell thereafter. Though the tumor cell
is the descendant of the cell whose genes sustained the first
mutation, there may be hundreds or thousands of generations
and many years between the ancestral cell that sustains the
first key genetic alteration and the progeny cell that receives
the second or third key event.
There are thus very significant intervals between the
first mutation and the second, and between the second and
the third. Following the second mutation, there may not be a
81. See DAVID S. SCHOTTENFELD & JOSEPH F. FRAUMENI, JR., CANCER
EPIDEMIOLOGY AND PREVENTION 68 (2d ed. 1996).
82. See SCI. AM., supra note 58, at 26; WEINBERG, supra note 5, at 57.
83. See WEINBERG, supra note 5, at 2.
84. See id. at 56, see also discussion infra notes 123-39 and accompanying
text.
85. See id. at 71, 76.
86. See ROBERT A. WEINBERG, RACING TO THE BEGINNING OF THE ROAD,
THE SEARCH FOR THE ORIGIN OF CANCER 251 (1996).
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third. After the third mutation, there may not be a fourth. It
is only the rare mutation to a key gene that ultimately
contributes to cancer. In fact, scientists believe that there is
"one fatal malignancy per 100 million billion cell
divisions. . . ."" Most genetic mutations in somatic cells are
simply not related to cell growth or to a cell's internal repair
function.88 Often a genetic mutation will trigger the death of
the cell and thus eliminate the possibility that this mutation
will be carried forward in a daughter cell.89 Thus, it is
extremely rare for a cell that has acquired one mutation to a
key gene to accumulate the three to six additional key
mutations required for cancer to develop.
As indicated above, each type of cancer has its own
unique genetic and pathological characteristics. The specific
manner in which any particular cancer proceeds through
mutational steps is not completely known, and because of the
different genetic makeup, environmental influences, and
lifestyle choices of different individuals, there are
innumerable paths that may eventually lead to cancer. In
order to discuss the development of cancer in any meaningful
way, however, one must first understand how cells divide.
Before focusing on the submicroscopic process of cell
division, however, it is useful first to pause momentarily and
assess the implications of what is apparent at the
macroscopic level. If one-third to two-fifths of all people
eventually contract cancer, then defining injury to include all
periods between the first key genetic mutation and the
development of a malignant tumor yields a peculiar result.
Under this definition, almost half the people would have to be
classed as "injured" or "diseased" for virtually their entire
lives-even though almost none of them had "cancer" until
they were in their seventies. Is "injury" really a useful or
proper term to characterize such a broad segment of the
population? If up to forty percent of the population is deemed
to be sick through eighty percent of their lives, then what
does it mean to be normal? Indeed, the question is more
complex because all people, even the people who do not
contract "cancer" within their lifetimes, are always carrying
within them thousands, if not tens or hundreds of thousands
87. WEINBERG, supra note 5, at 142.
88. See id.
89. See discussion infra notes 121-26 and accompanying text.
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of cells that bear genetic mutations that are the same, only
not as "advanced" as those that appeared as malignant
tumors in the people with cancer."0 Although these anomalies
in the use of the term "injury" do not dictate any given result,
nor help posit what definition of injury may best describe the
development of cancers, they do begin to place the issue in
perspective.
B. The Genetic Code
Cells are the basic building blocks of living things, and
the human body has about thirty trillion cells. 1 Each cell has
a nucleus, and the nucleus of each cell contains twenty-two
pairs of chromosomes, made up of DNA (deoxyribonucleic
acid), plus the sex chromosomes XX or XY.92 Chromosomes
are the structures upon which the hereditary instructions for
each particular cell are arranged. DNA is a large molecule
that carries the genetic information that cells need to
replicate. DNA acts like an intricate, lengthy instruction
manual or blueprint that tells each specific cell how to
perform its particular function in the body." The DNA found
in each type of cell also instructs that cell how to reproduce a
mirror image of itself.
DNA is arranged in segments of varying length and
complexity called genes. The 70,000 to 100,000 genes in each
cell are comprised of different combinations and sequences of
three to six billion base pairs of four nucleotides, adenine
("A"), thymine ("T"), cytosine ("C") and guanine ("G").94 These
bases are paired together chemically (by hydrogen bonds)
across the strands of the DNA double helix.95 Adenine (A) is
always paired with thymine (T), and guanine (G) is always
paired with cytosine (C). Thus, "an A appearing in one strand
of the helix always faces a T in the opposite strand; a C in one
strand inevitably confronts a G in the other. So the sequence
of ACCGGTCAA in one strand will be intertwined with a
partner sequence, TGGCCAGCTT in the other."96
Along the strands of the DNA these nucleotides are
90. See WEINBERG, supra, note 5 at 143, 156.
91. See SCI. AM., supra note 58, at 3.
92. See ROSS, supra note 19, at 4.
93. See id. at 7.
94. See id.; VOGELSTEIN & KINZLER, supra note 1, at 5.
95. See ROSS, supra note 19, at 4.
96. WEINBERG, supra note 5, at 9.
312 [Vol. 41
20011 TRIGGER OF COVERAGE FOR CANCER
grouped together in sixty-four different three-letter
combinations called codons.97 The genetic code is governed by
the order and sequence of these three-letter words along a
strand of DNA. Each codon encodes for one or more of the
twenty amino acids9" used in the synthesis of proteins which
are largely responsible for the structure and function of the
human organism. Perhaps most important among these
proteins are enzymes which function as biological catalysts
and permit chemical reactions to occur very rapidly at normal
life temperatures.99
Different proteins are activated according to the
instructions carried by the different sequences of base pairs
read as three-letter codons. "The letters CTG, for instance,
tell a cell to build the amino acid leucine and place it in a
specific spot in forming a protein, while the sequence GAT
describes aspartic acid."'00 Each gene is typically 30,000 base
pairs long.' There are 70,000 to 100,000 genes in each cell
and almost every cell in the body carries the entire genome,
i.e., all the genes necessary for the complete blueprint of the
living organism."' "The human genome is six billion base
pairs long. If spelled out and written as a book, the human
genome would be the size of a medical school library." 1 3 The
loss of a single base in a sequence of codons in a gene, or the
substitution of a T where a G should be, is enough to
constitute a mutation of that gene.
C. Cell Division
When a cell divides, it attempts to make an exact copy of
each of the chromosomes and genes contained within it. The
cell cycle is divided into four phases, each with its own
specialized characteristics:
G1 (Gapl) Phase: The Gap 1 phase is a period in which
97. See ROSS, supra note 19, at 6.
98. See id.
99. See Hereditary, Molecular Genetics, DNA as an Information Carrier
(1999) <http://www.britannica.com/bcom/eb/article/4/0,5716,120934+4+111157,
0O.html>. The DNA does not convey these instructions to the proteins directly,
but does so by means of messenger RNA (ribonucleic acid) and transfer RNA
which effects the protein synthesis outside of the nucleus of the cell in the
cytoplasm. See id.
100. WALDHOLZ, supra note 71, at 23.
101. See ROSS, supra note 19, at 7.
102. See WEINBERG, supra note 5, at 6-7.
103. ROSS, supra note 19, at 7.
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the cell increases in size and prepares to duplicate its
DNA by producing the necessary proteins for DNA
synthesis.
S (Synthesis) Phase: In the "S" phase, synthesis of DNA
occurs with precise duplication of chromosomes. This
permits the cell to divide into two daughter cells, each
with a complete copy of DNA.
G2 (Gap2) Phase: In the Gap2 phase, the cell again
undergoes growth and protein synthesis so that it will
have enough protein for two cells.
M (Mitosis) Phase: In the mitosis phase, the enlarged
parent cell divides to produce daughter cells.
04
With the completion of the M phase, cells which will
continue to divide return to G1 and the cycle begins again.'
Most critical for an understanding of cancer development is
the fact that the cycle of cell division is marked by periods of
inactivity or checkpoints at which a cell either repairs
damaged genes, or sends a signal that activates programmed
cell death (apoptosis). The principal checkpoint appears at
the G1/S boundary.!6 A second such checkpoint or gateway
which is less understood, occurs at the G2/M boundary.' 7
Different types of cells vary widely in the rate at which
they divide.' 8 Epithelial cells, like those of the skin or which
line the colon, and red blood cells produced by the bone
marrow divide and replicate with high frequency, once every
two or three days.' 9 Others, such as nerve cells and muscle
cells, generally do not divide further in mature humans.
Liver cells retain the ability to divide, but typically do not do
so unless necessary to repair a wound."0
D. Genetic Mutation
Independent of external stimuli, cells do not always make
perfect copies of their DNA,"' and, as noted, DNA can also be
104. Id. at 17-22.
105. See ALISON & SARRAF, supra note 4, at 134.
106. See id.
107. See ROSS, supra note 19, at 23.
108. See IAN F. TANNOCK & RICHARD HILL, THE BASIC SCIENCE OF
ONCOLOGY 161 (3d ed. 1998).
109. See WEINBERG, supra note 5, at 80.
110. See id. at 60.
111. See ROSS, supra note 19, at 22; WEINBERG, supra note 5, at 59.
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damaged as a result of outside factors."2 Such imperfections
are corrected by the cell itself."' But if the damage to a cell's
DNA is not repaired (or the cell itself has not been destroyed
through apoptosis), a cell that contains a genetic mutation
will pass that mutation on to its daughter cell through cell
division that occurs as part of the cell cycle."4  Not all
mutations to genes are harmful. Indeed, genetic mutation (in
germline cells) lies at the heart of the process of natural
selection and evolution. There are good mutations as well as
bad mutations, but most mutations are neutral."'
Genetic mutations frequently occur spontaneously."' The
majority of spontaneous mutations occur due to the nature of
the DNA and the cell's metabolism. The cell's normal energy
metabolism releases millions of highly reactive molecular by-
products every day. Many of these are oxidants, "free
radicals," which have unpaired, highly reactive electrons."7
Like environmental toxins these indigenous molecules can
chemically alter molecules in the cell including the molecules
that make up the cell's DNA."8 "Immediately after DNA
polymerase-the enzyme responsible for DNA replication-
has copied a stretch of DNA, as many as one in every
thousand bases of the newly made DNA strand may be
incorrect, having been mistakenly inserted by the
polymerase. " 19 Scientists estimate that about 600,000 of the
three to six billion base pairs will have been erroneously
copied during a single round of DNA synthesis.2 °
Regardless of their origin, i.e., viral, environmental,
hereditary, or spontaneous, mutations to certain vital genes
which help regulate cell growth and repair are more
important than damage to other genes within a cell. These
critically important growth and repair genes are referred to
as oncogenes, tumor suppressor genes, and DNA repair genes.
Before examining how changes to the cell's key growth and
repair genes affect the development of cancer, however, it is
112. See discussion supra notes 47-52 and accompanying text.
113. See WEINBERG, supra note 5, at 257.
114. See id. at 59.
115. See ROSS, supra note 19, at 7.
116. See WEINBERG, supra note 5, at 59.
117. See id. at 88.
118. See id.
119. Id. at 89.
120. See ROSS, supra note 19, at 22.
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useful to step back and assess the significance of two of the
factors just discussed-the source of the mutation, and the
size of the gene that is mutated.
First, it is noteworthy that the body itself spontaneously
causes genetic mutations. Though most of the cell's copying
mistakes are corrected and not perpetuated in the DNA of
descendent cells, the fact that these errors occur
spontaneously changes the backdrop against which any
classification of "injury" must be read. The human body is
not a perfect system that occasionally receives an insult from
an external source, but a complex and fluid balancing act that
is always in the process of deterioration and repair. In this
context, courts that base the continuous trigger on actual
injury in the policy period should be careful about seizing a
single mutation of a minute piece of genetic information and
labeling it as an "injury" or evidence of "continuing" harm. To
do so risks turning what is, in essence, an innocuous and
normal biological process into an injurious event that carries
major legal significance.
Second, as noted, "injury" is also a problematic term to
describe minute changes to the infinitesimally tiny
nucleotides whose deletion or subtle sequential
rearrangement can constitute a genetic mutation. There are
between 70,000 and 100,000 genes in each cell and each gene
in turn is comprised of different sequences of four nitrogenous
bases"1 called nucleotides that form DNA's double helix.
Each cell thus contains billions of bases, i.e., specific units of
the nucleotides C, G, T, or A, arranged in different sequences.
For example, though some base sequences in genes are longer
and some are shorter, the substitution of a single base of
guanine by thymine, in a gene that has over 5,000 bases in its
sequence, is enough to constitute what is termed a "point
mutation."" These extremely subtle genetic changes can-if
many other internal and external events occur and many
other systems fail-be part of a process that yields dramatic
consequences decades later. But it is misleading to identify a
point mutation that occurs in 1965 by the same term used to
describe a metastatic tumor that appears thirty-five years
later in the year 2000. Indeed, if one does use that term to
describe the entirety of the process then, in effect, one is
121. Adenine, Thymine, Cytosine, and Guanine.
122. See WEINBERG, supra note 5, at 42.
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describing virtually all humans as being in a constant state of
injury.
E. Mutations in Key Growth Control and Repair Genes
Within the genome are certain key genes whose normal
function is to tell a cell when to divide, and/or when and how
genes within the cell must be repaired. These are called
oncogenes, tumor suppressor genes, and repair genes.
1. Oncogenes
Oncogenes are mutated forms of genes that are referred
to as proto-oncognes which, in healthy cells, encourage and
promote normal growth and cell division.2 3 Proto-oncogenes
encourage and promote the normal growth and division of
cells. When proto-oncogenes mutate to become carcinogenic
oncogenes, they stimulate excessive cell multiplication.'24
A cell communicates with the cells of surrounding tissue
through receptors on the surface of the cell. The
communication goes both ways, i.e., these receptors relay
signals from outside into the cell nucleus and from inside the
cell to other cells. 125 Normally, proto-oncogenes provide a code
for cellular proteins that allow them to relay signals to a cell's
nucleus, stimulating growth. The cellular proteins used in
the relay system are responding to signals from other
neighboring cells.2 6 This signaling process involves a series
of steps in which information encoded in proteins is passed
along in a chain-like "bucket brigade" from the exterior cell
membrane to the cell's inner core. 7 The signaling process
ends in the nucleus with the activation of transcription
factors that are sent to the promoter regions of genes which
trigger cell division.'
During the life of a cell, proto-oncogenes along the
message pathway may mutate. When mutated, the proto-
oncogenes become oncogenes that keep the path continuously
active when it should be quiescent.1 9 Unlike proto-oncogenes,
123. See ROSS, supra note 19, at 32.
124. See VOGELSTEIN & KINZLER, supra note 1, at 205.
125. See SCI. AM., supra note 58, at 4.
126. See WEINBERG, supra note 5, at 97.
127. See SCI. AM., supra note 58, at 4.
128. See ROSS, supra note 19, at 32-33.
129. See VOGELSTEIN & KINZLER, supra note 1, at 205.
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oncogenes thus divorce cell proliferation from the complex set
of growth and anti-growth signals received from neighboring
cells. They make a cell's replication mechanism responsive to
its own internally generated and ongoing growth stimulation
signals."' 0  Mutations that turn proto-oncogenes into
oncogenes are rare, occurring in fewer than one-in-a-million
cell divisions.' 3 ' When this one-in-a-million risk materializes,
however, the oncogenes behave like a stuck accelerator on a
car, constantly urging it forward.13 "There are presently
nearly 200 known oncogenes that, under certain conditions,
can contribute to the release of cells from the normal controls
of proliferation, death, migration and adhesion to cause
neoplastic transformation." 3
2. Tumor Suppressor Genes
Unlike proto-oncogenes which stimulate the cell cycle,
tumor suppressor genes normally inhibit the cycle of cell
growth and division.'34 Like oncogenes, the tumor suppressor
genes operate at many sites from outside the cell to the cell
surface to the nucleus. In normal cells, tumor suppressor
genes function to stop or to slow the cell cycle until damaged
or incorrectly copied DNA can be repaired."5  Other tumor
suppressor genes help trigger cell death if it is sensed that
the DNA damage is too extreme to be repaired."'
Mutations in tumor suppressor genes cause the cell to
ignore one or more of the components of the network of
inhibitory signals."7 This removes the brakes from the cell
cycle and results in a higher rate of cellular division. Though
estimates are imprecise, there are thought to be as many as
three to four dozen distinct tumor suppressor genes.3
The most widely known tumor suppressor gene is p 5 3.
The p53 tumor suppressor gene is involved in a wide range of
130. See WEINBERG, supra note 5, at 107.
131. See id. at 56.
132. See WEINBERG, supra note 5, at 251; ALISON & SARRAF, supra note 4, at
65.
133. ROBIN HESKETH, THE ONCOGENE AND TUMOUR SUPPRESSOR GENE
FACTS BOOK 5 (2d ed. 1997).
134. See ROSS, supra note 19, at 45.
135. See BISHOP & WEINBERG, supra note 3, at 133.
136. See TANNOCK & HILL, supra note 108, at 107.
137. See WEINBERG, supra note 5, at 68-69.
138. See id. at 77.
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tumors.'39 In fact, more than fifty percent of cancerous cells
lack a functional p53 protein. 4 ° Also widely known are
BRCA1 and BRCA2, tumor suppressor genes which are
involved in ovarian and breast cancer.141
The deactivation of a tumor suppressor gene is even less
likely to occur than the mutation of a proto-oncogene-a one-
in-a-billion chance.12  This is because tumor suppressor
genes, like almost all genes in the body, are present in two
copies, one from the mother and one from the father. The loss
of one tumor suppressor gene will not cause problems-the
remaining copy is usually sufficient by itself to perform the
tumor suppressor function.' In about one in a thousand
cases, however, both versions of the same gene
(heterozygosity) are lost because the gene sequence present
on one chromosome is replaced by the corresponding sequence
carried by its partner.144 When this happens after one of the
tumor suppressor genes has been mutated, the still intact or
proper copy of the tumor suppressor gene may be lost, i.e.,
replaced by the duplicated copy of the mutated version of the
gene. Thus, the direct mutation of a tumor suppressor gene,
which occurs once per every million cell divisions, must be
multiplied by the one in one thousand frequency of loss of
heterozygosity, resulting in the loss of a functional tumor
suppressor gene only once per every billion cell divisions. 4'
3. DNA Repair Genes
Along with proto-oncogenes and tumor suppressor genes,
DNA repair genes are believed to be key genes in causing
cancer. These are genes that in ordinary operation help
ensure that each strand of genetic information is accurately
copied during the course of cell division. The cellular
mechanisms charged with repairing DNA consist of a large
group of proteins, some of which recognize damaged DNA
segments, others which cut them out, and still others which
substitute the excised segments with new ones that restore
139. See ALISON & SARRAF, supra note 4, at 183.
140. See WEINBERG, supra note 5, at 77.
141. See SCI. AM., supra note 58, at 13.
142. See WEINBERG, supra note 5, at 76.
143. See ALISON & SARRAF, supra note 4, at 74.
144. See ROSS, supra note 19, at 48; WEINBERG, supra note 5, at 76.
145. See WEINBERG, supra note 5, at 76.
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the proper base sequence.'46 Because DNA replication in cell
division is prone to error, it is critical that the repair genes
properly perform their tasks. Mutations in DNA repair genes
lead to an increase in the frequency of other mutations. 47
F. Cancer Promoters
In addition to endogenous or exogenous mutagens that
cause genetic mutations there are other agents called
"promoters" which contribute to the development of cancer by
speeding up the cell cycle. Substances such as alcohol,
asbestos, and estrogen are relatively weak mutagens
themselves, but contribute to or promote the development of
cancer in various ways. Other toxic agents, like cigarette
smoke, contain chemicals which both initiate the process by
causing mutation and promote it as well.' 49  Some such
promoters simply cause the DNA in cells to be copied more
frequently, thus creating increased possibilities of a mistake.
Estrogen, for example, is a fully natural hormone that
drives proliferation of cells lining the milk ducts during the
menstrual cycle and pregnancy. The monthly replication of
these cells is followed by their death. Women of the present
era tend to menstruate earlier, bear fewer children, bear
them later in life, and breast-feed for shorter periods of time.
These facts all combine to cause more menstrual cycles, more
estrogen production and more rounds of cell division.
Scientists now believe that estrogen, through this
mechanism, has become a promoter of breast cancer.'5 '
Similarly, the hepatitis B virus may promote the
development of liver cancer even though it does not have any
direct mutagenic effect on DNA. Although it does not directly
damage DNA, the virus kills off cells in the livers of infected
persons.'52 Normal liver cells rarely divide and replicate.
Livers infected with the hepatitis B virus, however, are
constantly replacing dead cells. The higher rate of cell
division leads to a greater frequency of miscopied and/or
unrepaired liver cells, and ultimately to an increased risk of
146. See TANNOCK & HILL, supra note 108, at 58-66.
147. See WEINBERG, supra note 5, at 88.
148. See id. at 60.
149. See ROSS, supra note 19, at 60.
150. See WEINBERG, supra note 5, at 60.
151. See id. at 61.
152. See id. at 60.
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liver cancer.
Even after mutations to key growth or repair genes have
occurred, tumor development is far from assured. As
discussed below, other genetic mechanisms trigger cell death
and thus help check uncontrolled cell growth. Before
reviewing these mechanisms at work, however, it is useful
once again to observe the poor fit between normal definitions
of injury and the more fluid, dynamic character of cancer
development. As noted, the terms "injury" and "disease" seem
inapt because genetic mutations are infinitesimally minute,
can occur spontaneously during cell replication, and, to one
degree or another, affect the entire population all of the time.
But these are only some of the definitional problems. The
relative risks and probabilities that any such mutation will
develop into cancer must also be taken into account.
Damage to DNA and genetic mutation occurs almost
constantly in the human body-and almost never results in
cancer. The risk of a key mutation to any particular cell is
very low, and the risk that any particular genetic mutation
will be part of a sequence of important mutations that leads
to cancer is extremely unlikely. As discussed above, a
mutation that activates an oncogene occurs only once per
every million cell divisions. The chance for mutating a tumor
suppressor gene such that it becomes non-functional is one-
in-a-billion. Even when such a mutation does occur, it
usually does not otherwise lead to cancer. Between four to
seven such events or mutations to a single cell are necessary
before a malignant tumor will commence-and even then, as
will be discussed below, the cell must avoid apoptosis,
senescence, crisis, and somehow metastasize before human
fatality is likely to occur. There may be long intervals
between key mutations. The body produces ten million billion
cells over the course of an average life span."' There is a fatal
malignancy that develops in only about one in every 100
million billion cell divisions. 5'
On the other hand, within the thirty trillion cells of the
body, genetic damage is frequently occurring and almost as
frequently being repaired. As the discussion of oncogenes,
tumor suppressor genes, and DNA repair genes indicates, the
153. See id.
154. See id. at 142.
155. See id.
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body is in a constant state of error and self-correction. As
Professor Weinberg has explained, "So the rock-solid stability
of the cell's genetic data base is a mirage. The constancy of
our genome is the result of a high-wire balancing act, a
permanent struggle in which an ever-vigilant repair
apparatus continually fights off genetic chaos." 6
Advocates of a continuous trigger, when confronted with
(1) almost immeasurably small genetic alterations, which
(2) occur spontaneously as well as a result of exogenous
factors, and which (3) almost never lead to full-blown cancer,
will argue that none of this is relevant. Adopting what is
referred to as a "retrospective analysis," they contend that as
long as it is apparent through hindsight that the particular
genetic mutation did, in fact, appear somewhere in the chain
of events that eventually resulted in cancer, the term injury
is proper. As discussed later, however, such a retrospective
analysis can be more misleading than it is informative in the
context of cancer. Indeed, though a particular mutation,
when and if it occurs, might in some sense be considered
"injurious" if it is traceable to an external source (as opposed
to a hereditary or endogenous cause), it is inadvisable to
identify the very process of being alive-this "high wire
balancing act" in which mutation and repair are always
ongoing-as a state of injury, sickness, or disease.
G. Methods of Cell Death
In order to advance along the path to cancer, cells must
not just sustain mutations to the genes that (1) stimulate and
(2) inhibit cell growth and (3) influence DNA repair and/or
(4) be influenced by "promoters" that encourage the cell to
divide more frequently. They must also sustain mutations to
genes that are programmed to cause the death of the cell
upon the cell's perception of excessive growth, damage, or
mutation. There are at least three separate mechanisms of
cell death that must be overcome if cancer is to occur:
apoptosis, senescence, and crisis.
1. Apoptosis
Apoptosis is programmed cell death. It is a self-destruct
mechanism that triggers the death of a cell when genes
156. WEINBERG, supra note 5, at 90.
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encoded to receive such information perceive a defect, such as
the signal of a mutant protein product from an oncogene." 7 In
some manner that is still unclear, cells sense when they have
sustained serious damage to their DNA.'58 Rather than
attempting to repair such serious damage, they are wired to
commit suicide. Even very subtle abnormalities in the
internal growth regulating circuitry of cells can trigger the
programmed death of a cell. 9 For example, the introduction
of a "myc" oncogene into a normal cell seems not only to
stimulate excessive growth,' but to cause a signaling
imbalance that provokes many cells to trigger their apoptotic
death program."'
One of the reasons that damage to the p53 tumor
suppressor gene is so serious is that the p53 gene plays a role
not just in slowing down the cell cycle so that DNA repair
genes can do their work, but it is also responsible for
transmitting messages to those genes which trigger
programmed cell death.12 Thus, p53 tumor suppressor genes
have multiple tasks. When relatively minor DNA damage is
sustained, the p53 tumor suppressor gene will temporarily
halt the cell's growth so that repair may be effectuated. On
the other hand, where the damage is more severe and exceeds
the capabilities of the DNA repair machinery, the p53 protein
will determine whether apoptosis is the appropriate
response."'
2. Senescence
A second back-up system comes into play for cells with
genetic mutations that successfully evade apoptosis. Normal
cells are incapable of further reproducing themselves after
fifty or sixty replications.' This is because the chromosomal
tips, called telomeres, which contain 1,000 or more base
repeats of the TTAGGC sequence necessary for cell
157. See ALISON & SARRAF, supra note 4, at 171.
158. See WEINBERG, supra note 5, at 123.
159. See id. at 122.
160. See id. at 107-08.
161. See ALISON & SARRAF, supra note 4, at 183-84.
162. See id.
163. See id. ("The function of p53 has been likened to that of a molecular
policeman or guardian of the genome; when DNA is damaged, p53 accumulates
and switches off replication to allow time for DNA repair.... If repair fails, p53
may trigger apoptosis.").
164. See SCI. AM., supra note 58, at 10.
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replication, are shortened by dozens of nucleotide bases each
time a cell divides.165 After forty or fifty cell doublings, the
telomeres become worn down and shortened so that they lose
their ability to protect the tips of the cells' chromosomes. The
chromosomes consequently fuse end to end creating genetic
disarray that causes cells to stop growing and eventually die.
This telomeric collapse is called senescence and normally
prevents cells from excessive proliferation.' 6
3. Crisis
Cells whose p53 tumor suppressor genes are defective,
however, may not only avoid apoptosis, but senescence as
well. They are sometimes able to continue growing in spite of
the telomeric shrinkage and multiply for another ten or
twenty cell generations. Even these cells, however, usually
die by entering a phase known as crisis.6 7 In this phase, a
second internal cellular alarm is sounded, apparently
triggered by telomeres that have continued to shorten and
reach a critically short size. Cells of this type suddenly die in
large numbers during the crisis phase.68
H. Telomerase and Immortality
An extremely rare cell, however, will evade apoptosis,
senescence, and crisis, and go on to live as an "immortal cell"
that continues to replicate and proliferate indefinitely. Cells
of this type survive by the activation of a gene that is coded
for the production of the enzyme telomerase.'69 This enzyme,
almost entirely silent in healthy cell types (other than
embryonic cells), is actively present in almost all tumor cells
and systematically replaces telomeric segments that are cut
away from the chromosomal ends during the normal cell
cycle. 7° Thus, it maintains the integrity of the telomeres and
allows these cells to replicate endlessly. 7'
Even after surviving or evading the various mechanisms
of cell death, there remain significant obstacles to tumor
165. See WEINBERG, supra note 5, at 116.
166. See TANNOCK & HILL, supra note 108, at 145.
167. See SCI. AM., supra note 58, at 10.
168. See WEINBERG, supra note 5, at 129.
169. See ROSS, supra note 19, at 147.
170. See SCI. AM., supra note 58, at 11.
171. See WEINBERG, supra note 5, at 116.
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development. The fact of cell death and the multiple ways it
can occur, however, points up further inadequacies in the use
of the term "continuous injury" to describe all phases leading
up to the development of cancer. Although genetic mutations
in any given cell are commonplace, mutations that impact key
growth and repair genes are rare. Even after a cell has
sustained a mutation to one of its critical genes, it is possible
that the cell or group of cells with the mutant genes will die.
It may take a long time for a cell with one mutation to receive
a second or a third key mutagenic event. Though it may be
possible, in some sense, to describe the mutation itself as
"injury," it is apparent that the lengthy period of time in
between significant mutations should not be so described.
I. Further Obstacles to Tumor Development
1. Angiogenesis
Even if a cell has survived after damage to its proto-
oncogenes, tumor suppressor genes, and DNA repair
mechanism, and somehow evaded apoptosis, senescence, and
crisis, very significant hurdles remain before the mutant cell
can proliferate to any significant degree. First, incipient
tumors require constant nourishment and oxygen. As long as
the tumor cells remain less than a millimeter in diameter,
they can depend on the process of diffusion'72 to provide
nourishment with oxygen and to rid the cells of carbon
dioxide and the waste products of their metabolism.7 '
At the size of one millimeter, however, the process of
diffusion is inadequate to the demands of growth.'74 Before
long, cells within the cluster become starved or begin to choke
on their own waste materials. These cells become oxygen-
starved and die from a p53-mediated form of apoptosis. At
some point, the death rate of these cells from asphyxiation
and metabolic poisoning begins to approach the rate at which
these cells can regenerate themselves.'75 Any gains made
172. Diffusion is the movement of a substance from an area of high
concentration to an area of low concentration. In cells, the movement and
exchange gases, nutrients, and water through the cell membrane is
accomplished by this process.
173. See Ross, supra note 19, at 63.
174. See WEINBERG, supra note 5, at 145.
175. See ALISON & SARRAF, supra note 4, at 186.
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through cell proliferation are neutralized by attrition, and so
the size of this tumor cell clump remains constant. If
cancerous tumors did not grow larger than the size of a
pinhead, they would not present a medical problem.'76 Some
clusters of tumor cells may remain in this static, microscopic
state for years and maybe even decades.'77
In order to grow beyond the size of a millimeter, the
incipient tumor must obtain its own direct access to the blood
supply.' This process, called angiogenesis, involves the
construction of blood vessels and occurs when some cells in
the tumor cluster mimic the behavior of the normal cells
around them. The cells also secrete growth factors that
attract endothelial cells from nearby tissues, inducing them
to multiply and to grow capillaries into the clump of cluster
cells. "'79 At this point, the tumor can begin to grow
explosively.8 ° It remains unclear at this time, however, how
tumor cells acquire the ability to generate these in-growing
blood vessels.
2. Metastasis
Even where tumors develop their own blood supply
through the process of angiogenesis, they will rarely become
lethal unless they metastasize and colonize other sites in the
body. Of those patients who die from cancer, fewer than ten
percent succumb from tumors that continue to grow at their
point of origin.'8 ' In the great majority of cases the killers are
metastases-colonies of cancer cells that have left the site of
the original, primary tumor and have settled elsewhere in the
body.1 82
The process of metastasis is as yet little understood.' To
metastasize, however, major hurdles must be overcome.
First, cells within the primary tumor mass must escape the
barrier that surrounds their growth. Epithelial cell layers are
underlaid by a structural meshwork of proteins called the
176. See ROSS, supra note 19, at 63.
177. See WEINBERG, supra note 5, at 144.
178. See id. at 145.
179. See SCI. AM., supra note 58, at 124; BISHOP & WEINBERG, supra note 3,
at 196-99.
180. See WEINBERG, supra note 5, at 145.
181. See id. at 146.
182. See ALISON & SARRAF, supra note 4, at 110.
183. See WEINBERG, supra note 5, at 149.
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"basement membrane" that separates the epithelium from
connective tissue and circulation." An intact basement
membrane is usually impenetrable to cells, and any invasion
through it depends on the ability of cancer cells to release
proteases, enzymes specialized for breaking protein chains of
the basement membrane into tiny fragments.'85 Second, if
this membrane is breached, it may give tumor cells access to
blood vessels or the lymphatic system.'86 In either case,
individual cells or small clumps of cells may break off from
the principal tumor mass riding through these systems to
more distant sites.'87
Yet even when cancer cells do get into circulation, the
formation of secondary tumors is unlikely. The circulating
cell must attach to the inner lining of a blood vessel, cross
through it, pass through the basement membrane at the new
location, and then invade the tissue beyond and begin
multiplying. "The journey through the blood vascular system
is extremely hazardous as tumor cells get jostled in a series of
high speed collisions with the vessel walls and each other;
only a minority of blood borne cancer cells seem to survive
this traumatic experience." 8' Indeed, probably fewer than
one in 10,000 of the cancer cells that reach circulation survive
to form a new tumor at a distant site.'89
Once the tumor cells reach a new site, they encounter
further problems. Cancer cells follow the pathways of the
circulatory system and tend to lodge in the first capillary
network they encounter downstream.9 ° Not all such sites,
however, are receptive to transplanted cell colonies. Cells
contain internal regulatory mechanisms that make them
compatible or incompatible with neighboring cells. These
mechanisms, somewhat like telephone area codes, help
prohibit a cell from leaving its normal home and establishing
a colony in an incompatible "area code." 9' Other researchers
explain this phenomenon by a seed and soil analogy "likening
cancer cells to 'seeds,' which after being scattered on the
184. See ROSS, supra note 19, at 64.
185. See BISHOP & WEINBERG, supra note 3, at 199-200.
186. See TANNOCK & HILL, supra note 108, at 221-24.
187. See BISHOP & WEINBERG, supra note 3, at 201.
188. ALISON & SARRAF, supra note 4, at 110.
189. See SCI. AM., supra note 58, at 19.
190. See ALISON & SARRAF, supra note 4, at 111.
191. See SCI. AM., supra note 58, at 17.
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'wind,' grow only in sites - ('soil') that are congenial to their
survival and further growth."19
At this time, less is known about the process of
metastasis than is currently known about the process of
tumor formation. Theoretically, interactions between tumor
cells and the endothelial cells of the capillaries where the
movement of the tumor cell is arrested, initiate signaling
pathways that promote metastasis by inducing expression of
genes, which helps the colonizing tumor cell attach and
adhere to the new host tissue.9 '
The complex hurdles a mass of malignant cells must
overcome in creating its own blood supply and, then after
further maturation, in forming new tumors at other sites, are
significant for coverage analysis. If there is this much risk
and uncertainty to the development of cancer after a tumor
has formed, then courts should be doubly cautious about
labeling pre-cancerous groups of cells and/or initial genetic
mutations as injury or disease.
IV. IMPLICATIONS FOR TRIGGER ANALYSIS
A. The Process of Cancer Development Does Not Constitute
a Continuous Injury
Even this brief outline of cancer development makes it
apparent that, as the district court stated in Stonewall,"' it is
difficult to fit complex medical phenomena like "cancer" into
terms of ordinary language like "injury." As another cancer
researcher has likewise commented, "cancer is more complex
than an all-or-none phenomenon," and "a tumor cannot be
simply classified as either benign or malignant."9 ' Despite
the continuous thread that leads from the first critical genetic
mutation to a malignant tumor, there are numerous and
significant aspects to the process of cancer development that
do not match well with traditional definitions of injury,
sickness, or disease. These factors have been noted in the
foregoing discussion, but it is useful to review them again
here.
192. ALISON & SARRAF, supra note 4, at 112.
193. See TANNOCK & HILL, supra note 108, at 230-31.
194. Stonewall Ins. Co. v. Asbestos Claims Management Corp., No. 86 Civ.
9671(JSM), 1998 WL 405047, at *1 (S.D.N.Y. July 17, 1998).
195. ROSS, supra note 19, at 70-71.
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1. The Processes Underlying Cancer Development Are
Too Common to Be Called "Injury"
Somewhere between thirty-three and forty percent of all
people will contract cancer at some point in their lives.
Although most people will not get cancer until their seventies,
use of the continuous injury trigger would brand such persons
as "injured" from the time of childhood until death. More
significantly, even people who do not ever contract cancer
during their lifetime always have cells bearing genetic
mutations, some of which appear in critical oncogenes, tumor
suppressor genes, and DNA repair genes. In the context of
multistage development of cancer,196 cells are frequently
"initiated" with initial genetic alterations or mutations. As a
leading cancer researcher has observed:
However, studies of DNA structural changes in liver
following single very low initiating doses of carcinogens
showed considerable DNA fragmentation... indicating
that DNA damage and mutations were extensive even at
subcarcinogenic doses. On the basis of the known
mutation-inducing capability of such agents, many
mutations are induced in cells and numerous initiated
cells are likely to be induced by carcinogens even at the
low doses to which humans are usually exposed. Thus it is
very likely that adult organisms possess numerous
initiated cells in most organs, making initiation an
extremely common event that occurs frequently both
spontaneously and by induction, experimentally, or
otherwise, in animals as well as humans.'97
Therefore, according to the view that brands the mere
initiation of a DNA mutation in a cell as injury, everyone is
injured all the time.
2. There Are "Spontaneous" Mutations that Can Lead to
Cancer
A genetic mutation does not result solely from external
stimuli. The body's own metabolism and the nature of DNA
itself cause genetic mutations.' 9' As many as twenty-five
percent of all cancers would occur regardless of the adverse
196. See supra note 3.
197. Pitot, supra note 21, at 1613 (emphasis added).
198. See supra notes 81-82.
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effects of certain lifestyle choices and environmental factors. 99
Because the body itself produces genetic mutations, it is more
difficult to automatically brand mutation abnormal and
injurious.
3. Genetic Mutations Are Infinitesimally Minute
Minor alterations in any metabolic process can ultimately
lead to dramatic adverse consequences. It is odd, however, to
refer to the almost immeasurably tiny alteration of a single
gene or base in a single cell, by itself, as injury. This is
especially so when it is considered that these tiny alterations
can occur naturally within the body, and are occurring all the
time to all people, but that it is extremely rare that any
particular such alteration will lead to cancer.
4. The Chance of Developing Cancer from Any Particular
Genetic Mutation Is Extremely Low
The chance that a proto-oncogene will mutate into a
potentially cancer-producing oncogene is one in one million. °°
The chance that a cell will lose an effective tumor suppressor
gene is one in one billion.20 ' Even if such mutations occur, it
is likely that the cell will die by means of apoptosis,
senescence, and crisis. Thus, "cancer is usually held at bay
because it depends on a convergence of rare events that are
unlikely to occur in an average human lifespan.
In the tort context, before permitting parties to sue for
fear of cancer, courts like the California Supreme Court have
required a showing that it is more probable than not that
cancer would result because of a given exposure."' Although
different definitions of injury apply in different legal contexts,
it is nonetheless anomalous to require a demonstration that
cancer is probable in order to affix liability in the tort system,
yet to brand a genetic mutation as "injury" in the insurance
context, when the possibility that that mutation will lead to
cancer is negligible at best, is common.
199. See supra notes 81-82.
200. See supra note 131.
201. See WEINBERG, supra note 5, at 153.
202. Id. at 143.
203. See Potter v. Firestone Tire & Rubber Co., 6 Cal. 4th 965 (1993).
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5. There Is No New Injury in the Interval Between
Mutations
Even if one were to assume that the term "injury" could
usefully apply to each of the four to seven key genetic
mutations that lead to the development of a malignant tumor,
there are long intervals between such mutations.
Following each critical mutation, the descendants of the
recently mutated cell would need to multiply into a flock of
a million or more before the next one-in-a-million
mutation became likely in one of its descendants. This
expansion in cell population might take several years to a
decade, explaining the long intervals between the
successive steps in the process of tumor formation.0 4
It is true that a genetic mutation may carry with it a
tendency to make a cell replicate more frequently, thus
elevating the risk that the cell will acquire a second critical
mutation simply as a result of the cell's own tendency to mis-
copy its genome in the course of cell replication. Yet, this ill
effect is part and parcel of the injury associated with the
original mutation itself and not a further and additional
injury.
Taken by themselves, perhaps no single one of these
factors would dictate the rejection of the "continuous injury"
designation for cancer. Taken collectively, however, they
acquire a weight and force that cannot be ignored. Though
these factors do not necessarily point to the "correct" trigger,
they strongly suggest that it is not possible to justify a
continuous injury trigger in the latent phases of cancer cases
where the toxic agent is not absorbed and retained in the
body to cause further mutation.
B. Problems with Arguments in Favor of Continuous Trigger
Despite the problems in applying a continuous trigger to
cancer cases, it is likely that advocates of this coverage theory
will argue in favor of its use in all cancer cases oil three
separate grounds. They will likely claim (1) that each
replication of a damaged cell is a "new" injury, (2) that the
proliferation of damaged cells is a "new injury," and (3) that
under a "retrospective analysis," it is plain from hindsight
that even the initial genetic mutation constituted injury
204. WEINBERG, supra note 5, at 56.
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because in the end, cancer did, in fact, develop. While these
arguments are interesting, none of them justifies the
conclusion that "continuous injury" accurately describes all
phases of cancer development.
1. The Argument that Cell Replication Is New Injury
In the context of asbestos-related cancers, at least one
court has held that "[elach replication of a damaged cell
constitutes a new injury.""5 It is unclear to what extent this
statement was intended by the court to have meaning outside
the context of asbestos-related diseases where the carcinogen
remains in the body. It is likely that the same argument will
be made in other cancer cases where this is not the case. In
other cancer cases, however, the argument seems wrong.
If it is proper to characterize the original mutation itself
as "injury," there is no "new" injury to the cell during the
period between the first and second key mutations. During
this interval, the original injury persists and is replicated.
Similarly, if a cell accumulates two key genetic mutations,
and the second mutation is itself viewed as another "injury,"
there would not be any "new" injury after the occurrence of
the second key genetic mutation until such time as a third
critical mutation might occur. The mere persistence of a
mutation through its replication in daughter cells should not
be viewed as new injury for purposes of coverage analysis.
The fact that mutations to the genes which regulate a
cell's replication and repair mechanisms persist in the
daughter cells and help increase the chance for additional
mutations does not necessarily make such persistence "new"
injury. This elevated risk is itself not "new injury" but may
be viewed as simply a consequence of the original mutation,
or the preceding accumulation of them. For example, a
mutation that affects one of the cell's proto-oncogenes may
increase the rate of cell replication and make additional
mutations more likely. But until the additional mutation
occurs-if it ever does-this increased rate of cell replication
itself should properly be viewed as the persistence of the
original mutation to the proto-oncogene that has transformed
it into a mutant oncogene.
205. Stonewall Ins. Co. v. Asbestos Claims Management Corp., No. 86 Civ.
9671(JSM), 1998 WL 405047, at *2 (S.D.N.Y. July 17, 1998).
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2. The Argument that Cell Proliferation Is a New Injury
A variation of the first argument stems from the higher
rate of cell replication that occurs in cells that have sustained
mutations to critical growth and repair genes. Due to this
higher rate of replication, it is theorized that cells bearing a
particular mutation will increase in number more than they
would have if there had not been the mutation. With this
increase in number comes the elevated risk that one among
this greater number of cells will sustain a second mutation.
Again, the district court in the Stonewall case listed this
factor among those which persuaded it that there was "injury
in fact" during the latency period prior to the appearance of
asbestos-related cancer. "The medical testimony shows that
asbestos can contribute to the cancer process ... [by]
increas[ing] the rate of proliferation in already mutated cells
causing the body to have an increased number of such cells,
thereby increasing the risk of further mutations .... "'
Several points are pertinent here. First, the exact extent
of increased cell proliferation is unknown and, in any given
case, likely to be minimal. While it is believed that the
genetically altered cell "enjoys a proliferative advantage over
its normal neighbors,"2 7 this fact alone should hardly be
determinative. The cell "circuitry is configured to resist
destabilization by single malfunctioning components. Thus,
the activation of an oncogene or the deactivation of a tumor
suppressor gene will often have only minimal effects on the
proliferation of a cell." °' Cell proliferation, even in mutated
cells, is kept in check by the death of cells through apoptosis,
senescence, crisis, and anoxia. In most cases, these processes
of cell death either keep in check or cancel entirely this
increased number of cells. This is why, even when such
groups of cells form a tiny tumor, the overall size "may
remain.., static.., for years, possibly even decades."0 9
Indeed, if this were not the case, the multi-step process of
cancer that unfolds over three to five decades would be
telescoped into a period of eight to ten years. The fact that
this kind of telescoping does not occur indicates the extremely
subtle and marginal character of any increase in the overall
206. Id.
207. ALISON & SARRAF, supra note 4, at 37.
208. WEINBERG, supra note 5, at 142.
209. Id. at 144.
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number of cells that occurs during the interval between
mutations.
Second, as noted earlier, cells may proliferate as a result
of spontaneous mutations. These mutations may involve
infinitesimally minute alterations of nucleotides. And such
mutation and proliferation are an ongoing process in all
people at all times. The argument thus still involves
describing infinitesimally tiny changes that are ongoing at all
times in all people as "injury."
Third, in light of these realities, the tendency of mutated
cells to increase their number is meaningful only if it
ultimately leads to cancer. This eventuality is both unknown
and highly unlikely through most of the course of cancer
development. Thus, this is a factor that acquires meaning
only to the extent that one employs a retrospective analysis.
As discussed below, however, the retrospective analysis itself
is flawed.
3. The Argument that Under a Retrospective Analysis,
Hindsight Permits a Court to Conclude that Even the
First Genetic Mutation Was Destined to Lead to
Cancer
The retrospective analysis of continuing injury was first
utilized by the trial court in the Coordinated Asbestos
Coverage Cases that were reviewed by the appellate court in
Armstrong World Industries v. Aetna Casualty & Surety Co.1 °
There, the insurers argued that it was improper to term
subclinical changes to a person's tissue as "injury" when
ninety percent of the people who sustained such subclinical
changes never contracted an asbestos-related disease. In
response, the court explained that it was unconcerned with
the ninety percent who did not become injured. As the court
of appeals later affirmed:
In the present case, the trial court necessarily took a
retrospective point of view. In resolving the insurance
coverage questions, the court was concerned only with
individuals who have actually developed asbestos-related
diseases, and for such claimants, the court found that the
evidence permitted the inference that injury took place in
the past: "[Tihe asbestos medical evidence [establishes] in
retrospect that undiscovered injury existed during the
210. 52 Cal. Rptr. 2d 690 (Cal. Ct. App. 1996).
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asbestos exposure period and during the latency period in
the absence of exposure." 211
The ineradicable presence of asbestos fibers and the
ongoing exposure to asbestos in the lungs may have created
an aura of inevitability about asbestos diseases once they
actually developed. But the rarity and unpredictability of
genetic mutations make such a retrospective analysis
unpersuasive in the context of other cancers.
To classify one genetic mutation (out of thousands) that
occurred in 1975 as "injury" because, with the benefit of
hindsight, it was apparent in 2010 that the mutation
developed into cancer is to invoke a very peculiar use of the
term "injury." It makes the occurrence of "injury" in 1975
dependent upon (a) later events (i.e., further important
mutations) that were (b) not only contingent and
unpredictable in 1975, but (c) highly unlikely to happen. It is
additionally strange because the later mutations, if they
occur, may be caused by lifestyle choices and/or by factors
that are entirely unrelated to the first mutation; or, in fact,
they may be spontaneous in origin and thus, relate to no
outside factor at all.
The oddity of this retrospective thesis calls to mind the
analysis of an appellate court in DES coverage litigation. In
applying a continuous trigger in the DES context, the court in
American Home Products Corp. v. Liberty Mutual Insurance
Co. 212 barred the application of a coverage theory proffered by
one of the parties on the ground that it would reverse the
normal sequence of cause and effect and, in essence, require
the effect to precede the cause:
An effect never precedes its cause. The policies plainly
give coverage for injury that occurred during the policy
period and was caused by exposure to [the insured's]
products; injury occurring during the policy period could
not have been caused by an exposure that occurred
thereafter. 212
The so-called retrospective analysis, however, effectively
does the same. It labels an event injurious not by virtue of its
intrinsic harm or its contemporaneous appearance, but solely
by virtue of contingent and unlikely events that occurred
211. Id. at 704 (citation omitted).
212. 748 F.2d 760 (2d Cir. 1984).
213. Id. at 765.
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thereafter. In a real way, the retrospective analysis thus
makes the cause of the "injury" in 1975 the events which post-
date 1975 by many years; it is only because of these later
mutagenic events that cumulatively precipitate the
development of cancer, that the earlier genetic mutation
earns the title of "injury." A quick example illustrates the
problem.
Assume that an individual is exposed to vinyl chloride,
an agent that is known to cause liver cancer,214 for three years
between 1970 and 1973. As a result of that exposure, a proto-
oncogene mutates into an oncogene. Thereafter, the exposure
to vinyl chloride ceases. Vinyl chloride is not maintained in
the body for any length of time after termination of
exposure,215 and thus, the only residual effect from the vinyl
chloride is the genetic mutation.
At another job, this individual is later exposed to a
different carcinogen and sustains a second key genetic
mutation to the same cell in 1980. Throughout his life, he
has eaten a diet low in fruits and vegetables and has drunk
more alcohol than he should have. As a result, in 1987 and
1996 respectively, he sustains a third and fourth significant
mutation in the same cell. As a result of the increased cell
replications due to prior mutations and his continuing
exposures to a cancer promoter like alcohol, he sustains a
fifth mutation in the year 2000. By the year 2002, he has
been diagnosed with liver cancer. According to retrospective
analysis, the "bodily injury, sickness or disease" can be said to
have existed from 1970 onward, even though he did not
contract cancer until the year 2000 and did not sustain the
fourth and fifth mutations necessary to give rise to cancer
until 1996 and 2000 respectively.
In a second example, the same individual works at the
same job where he is exposed to vinyl chloride, and at the end
of 1973, he ceases that work but has an oncogene activated in
one of his cells. This individual, however, continues his
education and becomes an accountant and is not exposed to
214. See INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, 19 ARC
MONOGAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS
TO HUMANS 377-438 (1979) (This section evaluates vinyl chloride and polymers).
215. See T. GREEN & D. E. HATHWAY, The Biological Fate in Rats of Vinyl
Chloride in Relation to Its Oncogenicity, 11 CHEMICO-BIOLOGICAL
INTERACTIONS 545, 551-52 (1975).
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any further carcinogens in the workplace. In addition, he
exercises, eats a healthy diet, and drinks only occasionally.
As a result, he sustains a second mutation to that cell as a
result of spontaneous mis-copying in the course of cell
division in the year 1990, but he does not contract cancer.
Although the individual in the second example had
exactly the same cellular mutation as did the person in the
first example in 1973 and carried that mutation with him
over the next thirty years, his mutation is not deemed to be
an injury. On the other hand, the individual in the first
example is deemed to have been injured continuously, even
though the necessary subsequent events that made the first
mutation "injurious" did not occur until ten and twenty years
after the first mutation. The retrospective analysis,
therefore, does more than simply permit a court with the
benefit of hindsight to see an injury in 1973 that was real but
not apparent at the time. Instead, it is a perspective that
permits later contingent events to determine and to
completely recharacterize the nature of what originally
happened. This kind of analysis is not simply retrospective,
but transfiguring.
V. CONCLUSION: WHAT IS THE PROPER TRIGGER FOR CANCER
CASES?
The foregoing analysis suggests that a continuous trigger
is not appropriate in cancer cases where the toxic agent does
not remain in the body-at least for courts that seek to
ground the application of a continuous trigger on a finding of
"continuous injury" in successive policies periods. That the
processes associated with cancer development do not fit
within a continuous trigger, however, does not indicate which
alternative coverage triggers might apply. Several factors are
important to consider in deciding which trigger applies.
A. When the Offending Agent Remains
Where the offending agent remains in the body after the
external stimulus is withdrawn, the injurious exposure
continues. In these cases, "injury," albeit infinitesimal, could
be said to be ongoing throughout the period of time when the
toxic agent remained in the body. As long as the injurious
exposure continued, a court could plausibly apply a
continuous trigger despite the existence of the risks,
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unknowns, and improbabilities of cancer development
discussed in this article. This is, in essence, what courts
appear already to have done with respect to coverage for
asbestos-related cancers.
B. When the Offending Agent Does Not Remain
Where the offending agent does not remain in the body,
as in cases of exposure to human carcinogens like radon,16
vinyl chloride, 17 and ethylene oxide,218 the situation is more
problematic. In such cases, courts can only be reasonably
sure that an injury "in fact" has occurred during the periods
of exposure to the toxic agent and during the period when a
tumor has appeared or where it becomes more probable than
not that a tumor will appear. But here, two problems arise.
First, science at this point cannot determine when it becomes
more probable than not that a group of cells with mutations
will become cancerous. Second, a tumor may exist for some
time before it is detected or detectable. 9
Scientific advances in cancer detection, however, may
ameliorate some of this problem. The recent advances in the
use of CT scans to image lung cancer tumors has permitted
physicians to detect tumors the size of a grain of rice instead
of the size of an orange, as detectable with traditional chest
X-rays. While the use of the CT scan technique is still
preliminary, it may detect lung tumors two to three years
earlier than before, and at a time when they may be
successfully removed. This boosts the survival rate by up to
eighty percent.20 Although the CT scan technique is far more
important to patients and clinicians than it is to coverage
216. See INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, 43 IARC
MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS
TO HUMANS 173-259 (1988) (This section evaluates radon).
217. See GREEN & HATHWAY, supra note 215.
218. See INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, 60 IARC
MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS
TO HUMANS 73-159 (1994) (This section evaluates ethylene oxide).
219. The court in Eagle-Picher Industries v. Liberty Mutual Insurance Co.,
829 F.2d 227 (1st Cir. 1987), described similar problems in determining when
asbestos-related diseases were diagnosed and/or diagnosable.
220. See Claudia I. Henschke et al., Early Lung Cancer Action Project:
Overall Design and Findings from Baseline Screening, THE LANCET, July 10,
1999, at 19-105; EMMA Ross, Study Suggests More Precise Lung Cancer
Screening Could Save Lives (July9, 1999) <http://www.sfgate.com/cgi-
bin/article.cgi?file=/news/archive/1999/07/09/
international1043EDT0577.DTL>.
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analysts, this and other advances in screening and detection
methods may make coverage analysis less hazardous. Other
early cancer detection methods that may help ascertain when
cancer becomes probable involve testing saliva, stools, or
urine for the presence of aberrant proteins present in cells
shed by the cluster of mutated cells. 21 Similar techniques
hope to detect cancer through the presence of the enzyme
telomerase, which permits cells that normally would die to
become immortal and cancerous.222 Though it is difficult to
predict at this time which test or screening measure will work
for which cancer, there is reason to believe that at least some
of the major problems associated with assigning a date of
injury to cancer might soon be significantly ameliorated.22
C. Fair and Straightforward Application of the Continuous
Trigger
In the meantime, courts that profess to apply the
continuous trigger on the basis of continuous injury should
employ the standard fairly and straightforwardly. This
means that if there is no competent factual basis for finding
injury during the latency period after injurious exposure to a
substance has ceased, but before symptoms appear, then
coverage should not be triggered during that time.
The Illinois Supreme Court in Zurich Insurance Co. v.
Raymark Industries, Inc.224 reached such a conclusion. It
affirmed a trial court ruling that denied application of a
continuous trigger to the latency period between exposure to
asbestos and the appearance of the physical symptoms of
asbestos-related diseases or injuries. The Illinois Supreme
Court upheld the trial court's ruling because the evidence was
simply insufficient to support the blanket conclusion sought
by the insured that asbestos-related "disease progresses in
every case after exposure ceases."
225
By contrast, in the first opinion to apply the continuous
trigger, the Keene court dispensed with any detailed review of
the factual developments of asbestos-related diseases. It did
not need such evidence because as the court candidly
221. See WEINBERG, supra note 5, at 157-58.
222. See SCI. AM., supra note 58, at 62.
223. See id. at 65; WALDHOLZ, supra note 71.
224. 514 N.E.2d 150 (IlM. 1987).
225. Id. at 160-61.
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explained, it would apply a continuous trigger from the
moment of first exposure until the appearance of disease
symptoms even if "no cellular changes were known to occur
during [the latency] period."226 Courts that have based the
application of a continuous trigger on the determination that
injury continues through each policy period do not have the
Keene option. They should not resort to legal fiction and use
the so-called retrospective analysis, in effect, to adopt the
Keene approach, while claiming to be guided by the "facts."
226. Keene Corp. v. Insurance Co. of N. Am., 667 F.2d 1034, 1044 n.19 (D.C.
Cir. 1981), cert. denied, 455 U.S. 1007 (1982).
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